<!DOCTYPE html>
<html >
<head>
  <!-- Site made with Mobirise Website Builder v4.7.2, https://mobirise.com -->
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Mobirise v4.7.2, mobirise.com">
  <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1">
  <link rel="shortcut icon" href="assets/images/29103469-1691374120928478-3164988639104991232-n-128x128.png" type="image/x-icon">
  <meta name="description" content="Web Page Creator Description">
  <title>Bibliographie</title>
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:700,400&subset=cyrillic,latin,greek,vietnamese">
  <link rel="stylesheet" href="assets/bootstrap/css/bootstrap.min.css">
  <link rel="stylesheet" href="assets/mobirise/css/style.css">
  <link rel="stylesheet" href="assets/dropdown-menu/style.css">
  <link rel="stylesheet" href="assets/mobirise/css/mbr-additional.css" type="text/css">
  
  
  
</head>
<body>
  <section id="dropdown-menu-2btn-z" data-rv-view="89">

    <nav class="navbar navbar-dropdown navbar-fixed-top">

        <div class="container">

            <div class="navbar-brand">
                <a href="index.html" class="navbar-logo"><img src="assets/images/29103469-1691374120928478-3164988639104991232-n-128x128.jpg" alt="Mobirise"></a>
                <a class="text-white" href="index.html">CD d'autoformation et d'autoévaluation en IRM du cancer du Rectum</a>
            </div>

            <button class="navbar-toggler pull-xs-right hidden-md-up" type="button" data-toggle="collapse" data-target="#exCollapsingNavbar">
                <div class="hamburger-icon"></div>
            </button>

            <ul class="nav-dropdown collapse pull-xs-right navbar-toggleable-sm nav navbar-nav" id="exCollapsingNavbar"><li class="nav-item dropdown"><a class="nav-link link" href="page13.html" aria-expanded="false">Plan</a></li><li class="nav-item dropdown"><a class="nav-link link" href="page4.html" aria-expanded="false">Introduction</a></li><li class="nav-item"><a class="nav-link link" href="page5.html" aria-expanded="false">Matériels et Méthodes</a></li><li class="nav-item"><a class="nav-link link" href="page6.html" aria-expanded="false">Résultats</a></li><li class="nav-item"><a class="nav-link link" href="page9.html" aria-expanded="false">Discussion</a></li><li class="nav-item"><a class="nav-link link" href="page14.html">Bibliographie</a></li><li class="nav-item nav-btn"><a class="nav-link btn btn-warning" href="page2.html">EXERCICES</a></li></ul>

        </div>

    </nav>

</section>

<section class="engine"><a href="https://mobirise.me/o">one page site templates</a></section><section class="mbr-section mbr-section--relative mbr-section--fixed-size mbr-after-navbar" id="content5-15" data-rv-view="91" style="background-color: rgb(255, 255, 255);">
    
    <div class="mbr-section__container container mbr-section__container--first" style="padding-top: 93px;">
        <div class="mbr-header mbr-header--wysiwyg row">
            <div class="col-sm-8 col-sm-offset-2">
                <h3 class="mbr-header__text">Bibliographie</h3>
                
            </div>
        </div>
    </div>
    <div class="mbr-section__container container mbr-section__container--last" style="padding-bottom: 62px;">
        <div class="row">
            <div class="mbr-article mbr-article--wysiwyg col-sm-8 col-sm-offset-2"><p>[1]	“Word Health Organization: GLOBOCAN 2012 (IARC) Section of Cancer Information.”
</p><p>[2]	M. G. Tytherleigh and N. J. McC Mortensen, “Options for sphincter preservation in surgery for low rectal cancer,” Br. J. Surg., vol. 90, no. 8, pp. 922–933, Aug. 2003.
</p><p>[3]	De calan L, Gayet B, Bourlier P, Perniceni T. Cancer du rectum : anatomie chirurgicale, préparation à l’intervention, installation du patient. EMC (Elsevier Masson SAS, Paris), Techniques chirurgicales - Appareil digestif, 40-606, 2004.
</p><p>[4]	J. Faucheron, D. Voirin, and J. Legros, “La préservation des nerfs du pelvis dans la chirurgie du rectum.,” E-Mem Acad Natle Chir, no. 6, pp. 17–26, 2007.
</p><p>[5]	H. Kaur et al., “MR imaging for preoperative evaluation of primary rectal cancer: practical considerations,” Radiogr. Rev. Publ. Radiol. Soc. N. Am. Inc, vol. 32, no. 2, pp. 389–409, Apr. 2012.
</p><p>[6]	V. Gowdra Halappa et al., “Rectal imaging: part 1, High-resolution MRI of carcinoma of the rectum at 3 T,” AJR Am. J. Roentgenol., vol. 199, no. 1, pp. W35-42, Jul. 2012.
</p><p>[7]	G. Brown et al., “High-resolution MRI of the anatomy important in total mesorectal excision of the rectum,” AJR Am. J. Roentgenol., vol. 182, no. 2, pp. 431–439, Feb. 2004.
</p><p>[8]	J. Arigon, L. Henry, H. Damon, and P. Valette, Radioanatomie proctologique. EMC (Elsevier Masson SAS, Paris), Radiodiagnostic -Appareil digestif, 33-480-A-40 : 12 p. 2002.
</p><p>[9]	S. Paramasivam, A. Proietto, and M. Puvaneswary, “Pelvic anatomy and MRI,” Best Pract. Res. Clin. Obstet. Gynaecol., vol. 20, no. 1, pp. 3–22, Feb. 2006.
</p><p>[10]	N. Chen, P. Q. Min, Z. Y. Liu, B. Wu, K. Q. Yang, and C. Y. Lu, “Radiologic and anatomic study of the extraperitoneal space associated with the rectum,” AJR Am. J. Roentgenol., vol. 194, no. 3, pp. 642–652, Mar. 2010.
</p><p>[11]	M. J. Gollub et al., “Recognition of the anterior peritoneal reflection at rectal MRI,” AJR Am. J. Roentgenol., vol. 200, no. 1, pp. 97–101, Jan. 2013.
</p><p>[12]	R. B. O’Malley, M. M. Al-Hawary, R. K. Kaza, A. P. Wasnik, P. S. Liu, and H. K. Hussain, “Rectal imaging: part 2, Perianal fistula evaluation on pelvic MRI--what the radiologist needs to know,” AJR Am. J. Roentgenol., vol. 199, no. 1, pp. W43-53, Jul. 2012.
</p><p>[13]	S. Halligan and J. Stoker, “Imaging of fistula in ano,” Radiology, vol. 239, no. 1, pp. 18–33, Apr. 2006.
</p><p>[14]	R. G. Beets-Tan et al., “Measurement of anal sphincter muscles: endoanal US, endoanal MR imaging, or phased-array MR imaging? A study with healthy volunteers,” Radiology, vol. 220, no. 1, pp. 81–89, Jul. 2001.
</p><p>[15]	F. Berton, G. Gola, and S. R. Wilson, “Sonography of benign conditions of the anal canal: an update,” AJR Am. J. Roentgenol., vol. 189, no. 4, pp. 765–773, Oct. 2007.
</p><p>[16]	F. Berton, G. Gola, and S. R. Wilson, “Perspective on the Role of Transrectal and Transvaginal Sonography of Tumors of the Rectum and Anal Canal,” Am. J. Roentgenol., vol. 190, no. 6, pp. 1495–1504, Jun. 2008.
</p><p>[17]	R. Siegel, C. Desantis, and A. Jemal, “Colorectal cancer statistics, 2014,” CA. Cancer J. Clin., vol. 64, no. 2, pp. 104–117, Apr. 2014.
</p><p>[18]	G. Salerno, I. R. Daniels, G. Brown, A. R. Norman, B. J. Moran, and R. J. Heald, “Variations in pelvic dimensions do not predict the risk of circumferential resection margin (CRM) involvement in rectal cancer,” World J. Surg., vol. 31, no. 6, pp. 1313–1320, Jun. 2007.
</p><p>[19]	J. Ferlay et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” Int. J. Cancer, vol. 136, no. 5, pp. E359-386, Mar. 2015.
</p><p>[20]	N. Bossard et al., “Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM),” Eur. J. Cancer Oxf. Engl. 1990, vol. 43, no. 1, pp. 149–160, Jan. 2007.
</p><p>[21]	S. A. Mulder et al., “Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study,” Cancer Epidemiol., vol. 35, no. 5, pp. 442–447, Oct. 2011.
</p><p>[22]	B. Bressler, L. F. Paszat, Z. Chen, D. M. Rothwell, C. Vinden, and L. Rabeneck, “Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis,” Gastroenterology, vol. 132, no. 1, pp. 96–102, Jan. 2007.
</p><p>[23]	W. Atkin et al., “Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial,” Lancet Lond. Engl., vol. 381, no. 9873, pp. 1194–1202, Apr. 2013.
</p><p>[24]	H. A. Shah, L. F. Paszat, R. Saskin, T. A. Stukel, and L. Rabeneck, “Factors associated with incomplete colonoscopy: a population-based study,” Gastroenterology, vol. 132, no. 7, pp. 2297–2303, Jun. 2007.
</p><p>[25]	S. H. Park et al., “CT colonography for detection and characterisation of synchronous proximal colonic lesions in patients with stenosing colorectal cancer,” Gut, vol. 61, no. 12, pp. 1716–1722, Dec. 2012.
</p><p>[26]	G. Y. Locker et al., “ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 24, no. 33, pp. 5313–5327, Nov. 2006.
</p><p>[27]	P. Rousset and C. Hoeffel, “Tumeurs du rectum : aspects IRM et scanner,” J. Radiol., vol. 88, no. 11, Part 1, pp. 1679–1687, Nov. 2007.
</p><p>[28]	B.-L. Yang, W.-J. Shao, G.-D. Sun, Y.-Q. Chen, and J.-C. Huang, “Perianal mucinous adenocarcinoma arising from chronic anorectal fistulae: a review from single institution,” Int. J. Colorectal Dis., vol. 24, no. 9, pp. 1001–1006, Sep. 2009.
</p><p>[29]	M. De Vargas Macciucca et al., “Rectal villous tumours: MR features and correlation with TRUS in the preoperative evaluation,” Eur. J. Radiol., vol. 73, no. 2, pp. 329–333, Feb. 2010.
</p><p>[30]	C. H. Holdsworth et al., “CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor,” AJR Am. J. Roentgenol., vol. 189, no. 6, pp. W324-330, Dec. 2007.
</p><p>[31]	P. Quirke and M. F. Dixon, “The prediction of local recurrence in rectal adenocarcinoma by histopathological examination,” Int. J. Colorectal Dis., vol. 3, no. 2, pp. 127–131, Jun. 1988.
</p><p>[32]	P. Quirke et al., “Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial,” Lancet Lond. Engl., vol. 373, no. 9666, pp. 821–828, Mar. 2009.
</p><p>[33]	R. G. H. Beets-Tan and G. L. Beets, “Rectal cancer: review with emphasis on MR imaging,” Radiology, vol. 232, no. 2, pp. 335–346, Aug. 2004.
</p><p>[34]	MERCURY Study Group, “Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study,” BMJ, vol. 333, no. 7572, p. 779, Oct. 2006.
</p><p>[35]	T. Akasu et al., “Thin-section MRI with a phased-array coil for preoperative evaluation of pelvic anatomy and tumor extent in patients with rectal cancer,” AJR Am. J. Roentgenol., vol. 184, no. 2, pp. 531–538, Feb. 2005.
</p><p>[36]	J. S. K. Goh, J. P. N. Goh, and G. K. L. Wansaicheong, “Methylcellulose as a Rectal Contrast Agent for MR Imaging of Rectal  Carcinoma,” Am. J. Roentgenol., vol. 178, no. 5, pp. 1145–1146, May 2002.
</p><p>[37]	M.-J. Kim et al., “Preoperative MRI of Rectal Cancer With and Without Rectal Water Filling: An Intraindividual Comparison,” Am. J. Roentgenol., vol. 182, no. 6, pp. 1469–1476, Jun. 2004.
</p><p>[38]	A. Laghi et al., “Local staging of rectal cancer with MRI using a phased array body coil,” Abdom. Imaging, vol. 27, no. 4, pp. 425–431, Aug. 2002.
</p><p>[39]	A. G. Maier et al., “Staging of rectal cancer by double-contrast MR imaging using the rectally administered superparamagnetic iron oxide contrast agent ferristene and IV gadodiamide injection: results of a multicenter phase II trial,” J. Magn. Reson. Imaging JMRI, vol. 12, no. 5, pp. 651–660, Nov. 2000.
</p><p>[40]	A. Slater, S. Halligan, S. A. Taylor, and M. Marshall, “Distance between the rectal wall and mesorectal fascia measured by MRI: Effect of rectal distension and implications for preoperative prediction of a tumour-free circumferential resection margin,” Clin. Radiol., vol. 61, no. 1, pp. 65–70, Jan. 2006.
</p><p>[41]	M. Hori et al., “Uterine tumors: comparison of 3D versus 2D T2-weighted turbo spin-echo MR imaging at 3.0 T--initial experience,” Radiology, vol. 258, no. 1, pp. 154–163, Jan. 2011.
</p><p>[42]	H. Kim et al., “Rectal cancer: comparison of accuracy of local-regional staging with two- and three-dimensional preoperative 3-T MR imaging,” Radiology, vol. 254, no. 2, pp. 485–492, Feb. 2010.
</p><p>[43]	J. J. Fütterer, D. Yakar, S. P. Strijk, and J. O. Barentsz, “Preoperative 3T MR imaging of rectal cancer: local staging accuracy using a two-dimensional and three-dimensional T2-weighted turbo spin echo sequence,” Eur. J. Radiol., vol. 65, no. 1, pp. 66–71, Jan. 2008.
</p><p>[44]	R. F. A. Vliegen et al., “Rectal cancer: MR imaging in local staging--is gadolinium-based contrast material helpful?,” Radiology, vol. 234, no. 1, pp. 179–188, Jan. 2005.
</p><p>[45]	S. Bipat, A. S. Glas, F. J. M. Slors, A. H. Zwinderman, P. M. M. Bossuyt, and J. Stoker, “Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis,” Radiology, vol. 232, no. 3, pp. 773–783, Sep. 2004.
</p><p>[46]	R. G. Beets-Tan et al., “Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery,” Lancet Lond. Engl., vol. 357, no. 9255, pp. 497–504, Feb. 2001.
</p><p>[47]	M. Urban et al., “MR imaging for the preoperative planning of sphincter-saving surgery for tumors of the lower third of the rectum: use of intravenous and endorectal contrast materials,” Radiology, vol. 214, no. 2, pp. 503–508, Feb. 2000.
</p><p>[48]	B. Glimelius, L. Påhlman, A. Cervantes, and ESMO Guidelines Working Group, “Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., vol. 21 Suppl 5, pp. v82-86, May 2010.
</p><p>[49]	H. A. Wieder et al., “Rectal cancer: MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor-free circumferential resection margins and long-term survival,” Radiology, vol. 243, no. 3, pp. 744–751, Jun. 2007.
</p><p>[50]	C. Bartram and G. Brown, “Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging,” Gastroenterol. Clin. North Am., vol. 31, no. 3, pp. 827–839, Sep. 2002.
</p><p>[51]	L. Blomqvist et al., “Rectal tumour staging: MR imaging using pelvic phased-array and endorectal coils vs endoscopic ultrasonography,” Eur. Radiol., vol. 10, no. 4, pp. 653–660, 2000.
</p><p>[52]	M. J. Lahaye et al., “Imaging for predicting the risk factors--the circumferential resection margin and nodal disease--of local recurrence in rectal cancer: a meta-analysis,” Semin. Ultrasound. CT MR, vol. 26, no. 4, pp. 259–268, Aug. 2005.
</p><p>[53]	E. Al-Sukhni et al., “Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis,” Ann. Surg. Oncol., vol. 19, no. 7, pp. 2212–2223, Jul. 2012.
</p><p>[54]	S. V. R. C. Wolberink, R. G. H. Beets-Tan, D. F. M. de Haas-Kock, E. J. van de Jagt, M. M. Span, and T. Wiggers, “Multislice CT as a primary screening tool for the prediction of an involved mesorectal fascia and distant metastases in primary rectal cancer: a multicenter study,” Dis. Colon Rectum, vol. 52, no. 5, pp. 928–934, May 2009.
</p><p>[55]	A. Taylor, A. Slater, N. Mapstone, S. Taylor, and S. Halligan, “Staging rectal cancer: MRI compared to MDCT,” Abdom. Imaging, vol. 32, no. 3, pp. 323–327, Jun. 2007.
</p><p>[56]	R. Vliegen et al., “The accuracy of Multi-detector row CT for the assessment of tumor invasion of the mesorectal fascia in primary rectal cancer,” Abdom. Imaging, vol. 33, no. 5, pp. 604–610, Sep. 2008.
</p><p>[57]	F. G. M. Taylor et al., “One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer,” Br. J. Surg., vol. 98, no. 6, pp. 872–879, Jun. 2011.
</p><p>[58]	F. Peschaud et al., “Accuracy of magnetic resonance imaging in rectal cancer depends on location of the tumor,” Dis. Colon Rectum, vol. 48, no. 8, pp. 1603–1609, Aug. 2005.
</p><p>[59]	G. Brown et al., “Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison,” Radiology, vol. 227, no. 2, pp. 371–377, May 2003.
</p><p>[60]	C. Wang et al., “Patterns of neoplastic foci and lymph node micrometastasis within the mesorectum,” Langenbecks Arch. Surg., vol. 390, no. 4, pp. 312–318, Aug. 2005.
</p><p>[61]	J. G. Guillem et al., “cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 26, no. 3, pp. 368–373, Jan. 2008.
</p><p>[62]	N. Mir, S. A. Sohaib, D. Collins, and D. M. Koh, “Fusion of high b-value diffusion-weighted and T2-weighted MR images improves identification of lymph nodes in the pelvis,” J. Med. Imaging Radiat. Oncol., vol. 54, no. 4, pp. 358–364, Aug. 2010.
</p><p>[63]	D. M. J. Lambregts et al., “Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability,” Eur. Radiol., vol. 21, no. 12, pp. 2567–2574, Dec. 2011.
</p><p>[64]	M. J. Lahaye et al., “USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria,” Radiology, vol. 246, no. 3, pp. 804–811, Mar. 2008.
</p><p>[65]	D.-M. Koh et al., “Diagnostic accuracy of nodal enhancement pattern of rectal cancer at MRI enhanced with ultrasmall superparamagnetic iron oxide: findings in pathologically matched mesorectal lymph nodes,” AJR Am. J. Roentgenol., vol. 194, no. 6, pp. W505-513, Jun. 2010.
</p><p>[66]	D. M. J. Lambregts et al., “Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer,” Ann. Surg., vol. 253, no. 3, pp. 539–545, Mar. 2011.
</p><p>[67]	G. Brown, A. G. Radcliffe, R. G. Newcombe, N. S. Dallimore, M. W. Bourne, and G. T. Williams, “Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging,” Br. J. Surg., vol. 90, no. 3, pp. 355–364, Mar. 2003.
</p><p>[68]	R. J. Heald and R. D. Ryall, “Recurrence and survival after total mesorectal excision for rectal cancer,” Lancet Lond. Engl., vol. 1, no. 8496, pp. 1479–1482, Jun. 1986.
</p><p>[69]	I. D. Nagtegaal and P. Quirke, “What is the role for the circumferential margin in the modern treatment of rectal cancer?,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 26, no. 2, pp. 303–312, Jan. 2008.
</p><p>[70]	Tiret E. Exérèse totale du mésorectum et conservation de l’innervation autonome à destinée génito-urinaire dans la chirurgie du cancer du rectum. EMC (Elsevier Masson SAS), Techniques chirurgicales - Appareil digestif, 40-610, [Accessed: 28-Feb-2018].
</p><p>[71]	C. Hoeffel, C. Marcus, L. Arrivé, O. Bouché, and J. Tubiana, “[Postoperative imaging after colorectal surgery],” J. Radiol., vol. 90, no. 7–8 Pt 2, pp. 954–968, Aug. 2009.
</p><p>[72]	C. Hoeffel, L. Arrivé, N. Mourra, L. Azizi, M. Lewin, and J.-M. Tubiana, “Anatomic and Pathologic Findings at External Phased-Array Pelvic MR Imaging after Surgery for Anorectal Disease,” RadioGraphics, vol. 26, no. 5, pp. 1391–1407, Sep. 2006.
</p><p>[73]	Q. Denost and E. Rullier, “Intersphincteric Resection Pushing the Envelope for Sphincter Preservation,” Clin. Colon Rectal Surg., vol. 30, no. 5, pp. 368–376, Nov. 2017.
</p><p>[74]	E. Rullier, C. Laurent, F. Bretagnol, A. Rullier, V. Vendrely, and F. Zerbib, “Sphincter-saving resection for all rectal carcinomas: the end of the 2-cm distal rule,” Ann. Surg., vol. 241, no. 3, pp. 465–469, Mar. 2005.
</p><p>[75]	K. Komori et al., “Adequate Margins to Prevent Local Re-recurrence of Rectal Cancer: Viewpoint of Pathological Findings,” Anticancer Res., vol. 35, no. 12, pp. 6747–6754, Dec. 2015.
</p><p>[76]	K. F. Birbeck et al., “Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery,” Ann. Surg., vol. 235, no. 4, pp. 449–457, Apr. 2002.
</p><p>[77]	J.-Z. Lin et al., “Preoperative chemoradiotherapy creates an opportunity to perform sphincter preserving resection for low-lying locally advanced rectal cancer based on an oncologic outcome study,” Oncotarget, vol. 7, no. 35, pp. 57317–57326, Aug. 2016.
</p><p>[78]	E. Kapiteijn et al., “Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer,” N. Engl. J. Med., vol. 345, no. 9, pp. 638–646, Aug. 2001.
</p><p>[79]	D. Sebag-Montefiore et al., “Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial,” Lancet Lond. Engl., vol. 373, no. 9666, pp. 811–820, Mar. 2009.
</p><p>[80]	R. Sauer et al., “Preoperative versus postoperative chemoradiotherapy for rectal cancer,” N. Engl. J. Med., vol. 351, no. 17, pp. 1731–1740, Oct. 2004.
</p><p>[81]	M. Maas et al., “Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data,” Lancet Oncol., vol. 11, no. 9, pp. 835–844, Sep. 2010.
</p><p>[82]	B. D. P. O’Neill, G. Brown, R. J. Heald, D. Cunningham, and D. M. Tait, “Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer,” Lancet Oncol., vol. 8, no. 7, pp. 625–633, Jul. 2007.
</p><p>[83]	A. Habr-Gama and R. O. Perez, “Non-operative management of rectal cancer after neoadjuvant chemoradiation,” Br. J. Surg., vol. 96, no. 2, pp. 125–127, Feb. 2009.
</p><p>[84]	T. Borschitz, D. Wachtlin, M. Möhler, H. Schmidberger, and T. Junginger, “Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer,” Ann. Surg. Oncol., vol. 15, no. 3, pp. 712–720, Mar. 2008.
</p><p>[85]	E. Francois et al., “ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up.,” J. Clin. Oncol., vol. 34, no. 4_suppl, pp. 490–490, Feb. 2016.
</p><p>[86]	C. Aschele et al., “Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 29, no. 20, pp. 2773–2780, Jul. 2011.
</p><p>[87]	M. S. Roh et al., “The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.,” J. Clin. Oncol., vol. 29, no. 15_suppl, pp. 3503–3503, May 2011.
</p><p>[88]	F. A. Calvo et al., “18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation,” Int. J. Radiat. Oncol. Biol. Phys., vol. 58, no. 2, pp. 528–535, Feb. 2004.
</p><p>[89]	J. G. Guillem et al., “Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography,” Dis. Colon Rectum, vol. 43, no. 1, pp. 18–24, Jan. 2000.
</p><p>[90]	N. K. Kim et al., “Oncologic Outcomes After Neoadjuvant Chemoradiation Followed by Curative Resection With Tumor-Specific Mesorectal Excision for Fixed Locally Advanced Rectal Cancer,” Ann. Surg., vol. 244, no. 6, pp. 1024–1030, Dec. 2006.
</p><p>[91]	C. Capirci et al., “Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients,” Int. J. Radiat. Oncol. Biol. Phys., vol. 72, no. 1, pp. 99–107, Sep. 2008.
</p><p>[92]	R. F. A. Vliegen et al., “Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction,” Radiology, vol. 246, no. 2, pp. 454–462, Feb. 2008.
</p><p>[93]	S. Nougaret et al., “MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy,” Radiology, vol. 263, no. 2, pp. 409–418, May 2012.
</p><p>[94]	J. Shia et al., “Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome,” Am. J. Surg. Pathol., vol. 28, no. 2, pp. 215–223, Feb. 2004.
</p><p>[95]	B. Barbaro et al., “Restaging locally advanced rectal cancer with MR imaging after chemoradiation therapy,” Radiogr. Rev. Publ. Radiol. Soc. N. Am. Inc, vol. 30, no. 3, pp. 699–716, May 2010.
</p><p>[96]	A. M. Mandard et al., “Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations,” Cancer, vol. 73, no. 11, pp. 2680–2686, Jun. 1994.
</p><p>[97]	J. Suárez et al., “Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer,” Colorectal Dis. Off. J. Assoc. Coloproctology G. B. Irel., vol. 10, no. 6, pp. 563–568, Jul. 2008.
</p><p>[98]	B. Barbaro et al., “Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy,” Radiology, vol. 250, no. 3, pp. 730–739, Mar. 2009.
</p><p>[99]	A. Rullier, C. Laurent, V. Vendrely, B. Le Bail, P. Bioulac-Sage, and E. Rullier, “Impact of colloid response on survival after preoperative radiotherapy in locally advanced rectal carcinoma,” Am. J. Surg. Pathol., vol. 29, no. 5, pp. 602–606, May 2005.
</p><p>[100]	C.-C. Chen, R.-C. Lee, J.-K. Lin, L.-W. Wang, and S.-H. Yang, “How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy?,” Dis. Colon Rectum, vol. 48, no. 4, pp. 722–728, Apr. 2005.
</p><p>[101]	D.-M. Koh, I. Chau, D. Tait, A. Wotherspoon, D. Cunningham, and G. Brown, “Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging,” Int. J. Radiat. Oncol. Biol. Phys., vol. 71, no. 2, pp. 456–461, Jun. 2008.
</p><p>[102]	A. Suppiah et al., “Magnetic resonance imaging accuracy in assessing tumour down-staging following chemoradiation in rectal cancer,” Colorectal Dis. Off. J. Assoc. Coloproctology G. B. Irel., vol. 11, no. 3, pp. 249–253, Mar. 2009.
</p><p>[103]	R. C. Dresen et al., “Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumor confined to the rectal wall?,” Radiology, vol. 252, no. 1, pp. 71–80, Jul. 2009.
</p><p>[104]	L. Curvo-Semedo et al., “Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy--conventional MR volumetry versus diffusion-weighted MR imaging,” Radiology, vol. 260, no. 3, pp. 734–743, Sep. 2011.
</p><p>[105]	D. J. Kim et al., “Restaging of Rectal Cancer with MR Imaging after Concurrent Chemotherapy and Radiation Therapy,” Radiogr. Rev. Publ. Radiol. Soc. N. Am. Inc, vol. 30, no. 2, pp. 503–516, Mar. 2010.
</p><p>[106]	P. Therasse et al., “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada,” J. Natl. Cancer Inst., vol. 92, no. 3, pp. 205–216, Feb. 2000.
</p><p>[107]	O. Dworak, L. Keilholz, and A. Hoffmann, “Pathological features of rectal cancer after preoperative radiochemotherapy,” Int. J. Colorectal Dis., vol. 12, no. 1, pp. 19–23, 1997.
</p><p>[108]	S. H. Kim, J. Y. Lee, J. M. Lee, J. K. Han, and B. I. Choi, “Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer,” Eur. Radiol., vol. 21, no. 5, pp. 987–995, May 2011.
</p><p>[109]	Y.-S. Sun et al., “Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging,” Radiology, vol. 254, no. 1, pp. 170–178, Jan. 2010.
</p><p>[110]	M. Lambrecht et al., “Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results,” Int. J. Radiat. Oncol. Biol. Phys., vol. 82, no. 2, pp. 863–870, Feb. 2012.
</p><p>[111]	D. M. J. Lambregts et al., “Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study,” Ann. Surg. Oncol., vol. 18, no. 8, pp. 2224–2231, Aug. 2011.
</p><p>[112]	M. J. Park, S. H. Kim, S. J. Lee, K. M. Jang, and H. Rhim, “Locally advanced rectal cancer: added value of diffusion-weighted MR imaging for predicting tumor clearance of the mesorectal fascia after neoadjuvant chemotherapy and radiation therapy,” Radiology, vol. 260, no. 3, pp. 771–780, Sep. 2011.
</p><p>
</p><p><br></p></div>
        </div>
    </div>
    
</section>


  <script src="assets/web/assets/jquery/jquery.min.js"></script>
  <script src="assets/bootstrap/js/bootstrap.min.js"></script>
  <script src="assets/smooth-scroll/smooth-scroll.js"></script>
  <script src="assets/mobirise/js/script.js"></script>
  <script src="assets/dropdown-menu/script.js"></script>
  
  
</body>
</html>